Lisata Therapeutics, Inc. (LSTA)

Lisata Therapeutics (NASDAQ: LSTA - Get Free Report) will likely be issuing its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect the company to announce earnings of ($0.74) per share for the quarter. Interested persons may visit the the company's upcoming Q4 2025 earning results page for the latest details on

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws

Lisata Therapeutics Inc (NASDAQ:LSTA, FRA:8NE) said it has mutually terminated a licensing and collaboration agreement with China's Qilu Pharmaceutical, regaining full rights to its cancer drug candidate certepetide in the Greater China region. The February 2021 agreement granted Qilu exclusive rights to develop and commercialize certepetide in Mainland China, Hong Kong, Macau and Taiwan.

Lisata regains full development rights to certepetide in the Greater China Region Lisata regains full development rights to certepetide in the Greater China Region

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Lisata Therapeutics, Inc. (NASDAQ: LSTA) to Kuva Labs, Inc. for $4.00 per share in cash plus two non-tradeable contingent value rights payable under certain conditions is fair to Lisata shareholders. Halper Sadeh encourages Lisata shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersade.

BALA CYNWYD, Pa. , Jan. 21, 2026 (GLOBE NEWSWIRE) -- Brodsky and Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith. com) or Marc Ackerman (mackerman@brodskysmith.

Lisata Therapeutics Inc (NASDAQ:LSTA, FRA:8NE) said on Wednesday it has agreed to be acquired by privately held Kuva Labs in a cash deal valuing the clinical-stage drug developer at $4 per share, plus potential contingent payments tied to regulatory and licensing milestones. Under the terms of a binding term sheet, Kuva will launch a tender offer to buy all outstanding Lisata shares for $4 each in cash, with shareholders also eligible to receive up to $2 per share through two non-tradeable contingent value rights, Lisata said.

Stockholders to also receive two contingent value rights valued at $1 per share, each entitled to be received upon the achievement of certain milestones Offer represents an approximate 85% premium over the most recent closing price of Lisata stock BASKING RIDGE, N.J., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that it has entered into a binding term sheet to be acquired by Kuva Labs, Inc. (“Kuva”), a privately-held company.

Lisata Therapeutics Inc (NASDAQ:LSTA, FRA:8NE) said on Wednesday it has agreed to be acquired by privately held Kuva Labs in a cash deal valuing the...

Headline UK inflation climbed higher in December due to extra duties and rebounding airfares, but underlying measures remained unchanged. The consumer price...

BeyondSpring (NASDAQ: BYSI - Get Free Report) and Lisata Therapeutics (NASDAQ: LSTA - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, institutional ownership, analyst recommendations and risk. Risk and Volatility BeyondSpring has a beta of

Lisata Therapeutics, Inc. (NASDAQ: LSTA - Get Free Report)'s stock price fell 3.9% during trading on Friday. The company traded as low as $1.92 and last traded at $1.97. 29,264 shares changed hands during trading, an increase of 35% from the average session volume of 21,665 shares. The stock had previously closed at $2.05. Wall

Lisata Therapeutics, Inc. ( LSTA ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants John Menditto - Vice President of Investor Relations & Corporate Communications David Mazzo - President, CEO & Director James Nisco - Senior VP of Finance, Treasurer, CAO & Principal Financial and Accounting Officer Kristen Buck - Executive VP of R&D and Chief Medical Officer Conference Call Participants Lander Egaña-Gorroño Robert Sassoon - Water Tower Research LLC Peter Enderlin - MAZ Capital Advisors, LLC Brian Kemp Dolliver - Brookline Capital Markets, LLC, Research Division Presentation Operator Welcome to the Lisata Therapeutics Third Quarter 2025 Financial Results and Business Update Conference Call. [Operator Instructions] As a reminder, this call is being recorded today, Thursday, November 6, 2025.

Lisata Therapeutics Inc (NASDAQ:LSTA) has reported financial results for the third quarter, highlighting continued clinical progress for its lead investigational therapy, certepetide, and announcing strategic collaborations to expand its development and discovery capabilities. Certepetide, Lisata's proprietary investigational peptide, continues to be studied across multiple solid tumor types in combination with standard anti-cancer therapies.